The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 13, 2019

Filed:

Dec. 02, 2014
Applicant:

Brandeis University, Waltham, MA (US);

Inventor:

Isaac J. Krauss, Waltham, MA (US);

Assignee:

Brandeis University, Waltham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/117 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); A61K 39/21 (2006.01); C12N 15/10 (2006.01); C12P 19/34 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/117 (2013.01); A61K 39/21 (2013.01); C12N 15/1058 (2013.01); C12P 19/34 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5308 (2013.01); G01N 33/57415 (2013.01); G01N 33/57419 (2013.01); G01N 33/57423 (2013.01); G01N 33/57434 (2013.01); G01N 33/6854 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01); C12N 2310/16 (2013.01); C12N 2310/17 (2013.01); C12N 2310/351 (2013.01); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/162 (2013.01); G01N 2333/9121 (2013.01);
Abstract

The invention relates to an oligonucleotide including one or more modified nucleoside bases having the structure -B-L-A wherein for each of the modified nucleosides A is independently a monosaccharide or oligosaccharide, L is a linker molecule, and B is independently a pyrimidine or pyridine base linked to the sugar-phosphate backbone of the oligonucleotide; and wherein the oligonucleotide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nM. Immunogenic conjugates that include the oligonucleotide, and pharmaceutical compositions that include the oligonucleotide or the immunogenic conjugate are also disclosed. Various method of using the oligonucleotides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral or bacterial infection, treating a cancerous condition, and detecting a neutralizing antibody. A method is also disclosed for selecting the oligonucleotides using an alternative Selection of Modified Aptamers (SELMA).


Find Patent Forward Citations

Loading…